AVEO Pharmaceuticals Inc. (AVEO)

0.62
0.06 9.45
NASDAQ : Health Technology
Prev Close 0.68
Open 0.68
Day Low/High 0.61 / 0.69
52 Wk Low/High 0.56 / 3.59
Volume 7.53M
Avg Volume 2.60M
Exchange NASDAQ
Shares Outstanding 125.35M
Market Cap 77.49M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
J.P. Morgan Biotech Confab Live Chat

J.P. Morgan Biotech Confab Live Chat

TheStreet's Adam Feuerstein will give his impressions of the J.P. Morgan Healthcare Conference and answer readers' biotech investing questions.

AVEO Rises On Unusually High Volume (AVEO)

AVEO Rises On Unusually High Volume (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) is trading at unusually high volume Wednesday with 901,612 shares changing hands. It is currently at four times its average daily volume and trading up 39 cents (+2.8%).

AVEO Stock Falls On Unusually High Volume (AVEO)

AVEO Stock Falls On Unusually High Volume (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) is trading at unusually high volume Tuesday with 1.6 million shares changing hands. It is currently at seven times its average daily volume and trading down $2.80 (-16.3%).

Aveo Beats Onyx in Study of Dueling Kidney Cancer Drugs But Shares Still Fall

Aveo Beats Onyx in Study of Dueling Kidney Cancer Drugs But Shares Still Fall

Aveo will seek approval for its kidney cancer drug based on positive results from a late-stage study.

Stocks to Watch: Chesapeake, BP, Sears

Stocks to Watch: Chesapeake, BP, Sears

Chesapeake Energy and EnerVest will get $2.3 billion from France's Total for a 25% stake in a joint venture for oil drilling in the Utica Shale area of Ohio.

AVEO Pharmaceuticals, Inc. Announces Webcast And Conference Call

AVEO Pharmaceuticals, Inc. Announces Webcast And Conference Call

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that the AVEO management team will host a conference call on Tuesday, January 3, 2012 at 8:30 a.

AVEO Pharmaceuticals To Present At The 30th Annual J.P. Morgan Healthcare Conference

AVEO Pharmaceuticals To Present At The 30th Annual J.P. Morgan Healthcare Conference

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 30 th Annual J.

AVEO Announces Patient Enrollment In Phase 2 Clinical Trial Of Tivozanib In Combination With MFOLFOX6 In Patients With Advanced Colorectal Cancer

AVEO Announces Patient Enrollment In Phase 2 Clinical Trial Of Tivozanib In Combination With MFOLFOX6 In Patients With Advanced Colorectal Cancer

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the initiation of patient enrollment in an open-label, multicenter, randomized Phase 2 clinical trial, called BATON-CRC, evaluating tivozanib in combination ...

5 Stocks Setting Up to Break Out

5 Stocks Setting Up to Break Out

These stocks look poised to break out and trade higher from current levels.

AVEO Pharmaceuticals And Boehringer Ingelheim Announce Manufacturing Agreement For Ficlatuzumab

AVEO Pharmaceuticals And Boehringer Ingelheim Announce Manufacturing Agreement For Ficlatuzumab

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO’s ...

AVEO To Present Tivozanib Clinical Data At Upcoming Oncology Medical Congresses

AVEO To Present Tivozanib Clinical Data At Upcoming Oncology Medical Congresses

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported clinical data evaluating its lead product candidate tivozanib will be featured at the 3 rd European Multidisciplinary Meeting on...

AVEO Pharmaceuticals Reports Third Quarter 2011 Financial Results

AVEO Pharmaceuticals Reports Third Quarter 2011 Financial Results

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported consolidated financial results for the third quarter of 2011 and provided an update on the tivozanib clinical program.

AVEO Pharmaceuticals, Inc. Announces Timing For Third Quarter 2011 Financial Results, Webcast And Conference Call

AVEO Pharmaceuticals, Inc. Announces Timing For Third Quarter 2011 Financial Results, Webcast And Conference Call

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that financial results for the company’s third quarter ended September 30, 2011 will be released before the market opens on Wednesday, November 2, 2011.

AVEO Pharmaceuticals Inc. Stock Upgraded (AVEO)

AVEO Pharmaceuticals Inc. Stock Upgraded (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) has been upgraded by TheStreet Ratings from a sell to hold.

AVEO Pharmaceuticals Inc. Stock Downgraded (AVEO)

AVEO Pharmaceuticals Inc. Stock Downgraded (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) has been downgraded by TheStreet Ratings from from a hold to sell.

AVEO Pharmaceuticals, Inc. To Present At Upcoming Investment Conferences

AVEO Pharmaceuticals, Inc. To Present At Upcoming Investment Conferences

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that the company’s management will present a company overview at upcoming investment conferences.

AVEO Pharmaceuticals, Inc. To Present At The Canaccord Genuity 31st Annual Growth Conference

AVEO Pharmaceuticals, Inc. To Present At The Canaccord Genuity 31st Annual Growth Conference

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Canaccord Genuity 31 st Annual Growth Conference on Tuesday, August 9,...

AVEO Reports Second Quarter 2011 Accomplishments And Financial Results

AVEO Reports Second Quarter 2011 Accomplishments And Financial Results

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reviewed key second quarter accomplishments and reported consolidated financial results for the second quarter of 2011.

AVEO Pharmaceuticals, Inc. Announces Timing For Second Quarter 2011 Financial Results, Webcast And Conference Call

AVEO Pharmaceuticals, Inc. Announces Timing For Second Quarter 2011 Financial Results, Webcast And Conference Call

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that financial results for the company’s second quarter ended June 30, 2011 will be released before the market opens on Thursday, July 28, 2011.

More Hot Biotech Trades for Second Half 2011

More Hot Biotech Trades for Second Half 2011

These looming FDA drug approvals and clinical trial results are pivotal events in the lifeline of a biotech company.

Context Is Everything

It's highly unlikely the market will head straight down since tops and bottoms take time to form, regardless of any logical reason for a trend change.

AVEO Reaches New 52-Week High (AVEO)

AVEO Reaches New 52-Week High (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) hit a new 52-week high Wednesday as it is currently trading at $21.35, above its previous 52-week high of $21 with 106,116 shares traded as of 9:37 a.m. ET. Average volume has been 415,900 shares over the past 30 days.

AVEO Stock Hits New 52-Week High (AVEO)

AVEO Stock Hits New 52-Week High (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) hit a new 52-week high Monday as it is currently trading at $20, above its previous 52-week high of $19.99 with 221,714 shares traded as of 12:12 p.m. ET. Average volume has been 350,100 shares over the past 30 days.

AVEO Rises On Unusually High Volume (AVEO)

AVEO Rises On Unusually High Volume (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) is trading at unusually high volume Friday with 1.8 million shares changing hands. It is currently at 5.1 times its average daily volume and trading up 54 cents (+2.8%).

AVEO Pharmaceuticals Announces Closing And Exercise Of Over-Allotment Option For Recent Public Offering

AVEO Pharmaceuticals Announces Closing And Exercise Of Over-Allotment Option For Recent Public Offering

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has closed its previously announced underwritten public offering of common stock.

AVEO Stock Falls On Unusually High Volume (AVEO)

AVEO Stock Falls On Unusually High Volume (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) is trading at unusually high volume Wednesday with 1.2 million shares changing hands. It is currently at four times its average daily volume and trading down $2.02 (-10.6%).

AVEO Pharmaceuticals Prices Public Offering Of Common Stock

AVEO Pharmaceuticals Prices Public Offering Of Common Stock

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the pricing of an underwritten public offering of 5,750,000 shares of its common stock at a price of $17.

JPMorgan, AVEO: After-Hours Trading

JPMorgan, AVEO: After-Hours Trading

JPMorgan Chase and Scotts Miracle-Gro were among the stocks seeing trading interest in Tuesday's after-hours session.

AVEO Pharmaceuticals Announces Proposed Public Offering Of Common Stock

AVEO Pharmaceuticals Announces Proposed Public Offering Of Common Stock

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has commenced an underwritten public offering of shares of its common stock.

TheStreet Quant Rating: D- (Sell)